文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

低剂量与极低剂量贝伐珠单抗治疗早产儿视网膜病变:复发、追加治疗及12个月结局

Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
PubMed 文献 · Ophthalmology · 2022-06-01

这项掩蔽、多中心、剂量递减研究纳入120例1型早产儿视网膜病变患儿,评估低剂量与极低剂量玻璃体腔注射贝伐珠单抗后的12个月结局。结果显示视网膜结构结局良好,但多数患眼接受了追加治疗;严重病变复发率与剂量无关,但事后分析提示极低剂量组复发时间更早。

要点

  • 113只研究眼中62只(55%)和98只对侧眼中55只(56%)接受了追加治疗。
  • 研究眼中31只(27%)接受追加ROP治疗,31只(27%)因持续性无血管视网膜接受预防性激光治疗。
  • 极低剂量组研究眼复发时间(平均76.4天)短于低剂量组(平均85.7天)。

核心结论

  • 低剂量与极低剂量玻璃体腔注射贝伐珠单抗作为1型早产儿视网膜病变初始治疗后,视网膜结构结局很好,尽管许多患眼接受了追加治疗。
  • 严重早产儿视网膜病变的复发率与剂量无关,但事后数据驱动分析提示极低剂量组复发更早。

研究设计与样本

  • 掩蔽、多中心、剂量递减研究,纳入120例至少1眼患1型早产儿视网膜病变的早产儿,来自两项序贯剂量递减研究。
  • 研究眼接受低剂量(0.25 mg、0.125 mg、0.063 mg、0.031 mg)或极低剂量(0.016 mg、0.008 mg、0.004 mg、0.002 mg)玻璃体腔注射贝伐珠单抗;对侧眼(若也为1型)接受高一个剂量水平的贝伐珠单抗。
  • 4周时确定初始成功或失败后,临床管理由研究者酌情决定,包括所有追加治疗。

主要发现

  • 113只研究眼中62只(55%)和98只对侧眼中55只(56%)接受了追加治疗。
  • 研究眼中31只(27%)接受追加早产儿视网膜病变治疗,31只(27%)因持续性无血管视网膜接受预防性激光治疗。
  • 未发现追加早产儿视网膜病变治疗风险与初始贝伐珠单抗剂量相关的趋势。
  • 研究眼复发时间在极低剂量组(平均76.4天)短于低剂量组(平均85.7天)。
  • 12个月时,不良视网膜结局和前节异常均不常见(分别为3%和5%),10%可见视神经萎缩,中位屈光度为轻度近视(-0.31屈光度),29%的婴儿存在斜视。

关键数值与推荐

  • 主要结局指标为矫正年龄6个月时严重早产儿视网膜病变复发、追加治疗、视网膜及其他眼部结构结局,以及矫正年龄12个月时屈光不正。
  • 研究眼追加治疗指征包括追加早产儿视网膜病变治疗(27%)和因持续性无血管视网膜行预防性激光治疗(27%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 复发时间差异来自事后数据驱动分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Low-dose and very low-dose intravitreal bevacizumab (IVB) have been reported to be successful in short-term treatment of type 1 retinopathy of prematurity (ROP), down to an initial dose of 0.004 mg. We now report 12-month outcomes for these infants. DESIGN: Masked, multicenter, dose de-escalation study. PARTICIPANTS: One hundred twenty prematurely born infants with type 1 ROP. METHODS: A cohort of 120 infants with type 1 ROP in at least 1 eye from 2 sequential dose de-escalation studies of low-dose IVB (0.25 mg, 0.125 mg, 0.063 mg, and 0.031 mg) or very low-dose IVB (0.016 mg, 0.008 mg, 0.004 mg, and 0.002 mg) to the study eye; the fellow eye (if also type 1) received 1 dose level higher of IVB. After primary success or failure at 4 weeks, clinical management was at investigator discretion, including all additional treatment. MAIN OUTCOME MEASURES: Reactivation of severe ROP by 6 months corrected age, additional treatments, retinal and other ocular structural outcomes, and refractive error at 12 months corrected age. RESULTS: Sixty-two of 113 study eyes (55%) and 55 of 98 fellow eyes (56%) received additional treatment. Of the study eyes, 31 (27%) received additional ROP treatment, and 31 (27%) received prophylactic laser therapy for persistent avascular retina. No trend toward a higher risk of additional ROP treatment related to initial IVB doses was found. However, time to reactivation among study eyes was shorter in eyes that received very low-dose IVB (mean, 76.4 days) than in those that received low-dose IVB (mean, 85.7 days). At 12 months, poor retinal outcomes and anterior segment abnormalities both were uncommon (3% and 5%, respectively), optic atrophy was noted in 10%, median refraction was mildly myopic (-0.31 diopter), and strabismus was present in 29% of infants. CONCLUSIONS: Retinal structural outcomes were very good after low- and very low-dose IVB as initial treatment for type 1 ROP, although many eyes received additional treatment. The rate of reactivation of severe ROP was not associated with dose; however, a post hoc data-driven analysis suggested that reactivation was sooner with very low doses.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Freedman SF, Hercinovic A, Wallace DK, et al. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. Ophthalmology. 2022. PMID: 35660415. doi:10.1016/j.ophtha.2022.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。